Friday, May 16, 2014

Medical Compounding Laws Have Changed!!!

Have you noticed that many compounding pharmacies have changed their business model? Perhaps they even stopped producing a product for you. Many physician practices and medical spas have suddenly discovered that they can no longer obtain compounded products for their facilities. Many are scrambling to find a new supplier.  Many compounding pharmacies have closed and others have had to discover new ways to manufacture a product.  

There are a lot of problems associated with the changes in compounding laws. To make matters worse, the changes were sudden. Many believe that the law was enacted as a result of a meningitis epidemic in November of 2013. 




The Compounding Quality Act 

President Obama signed the Drug Quality and Security Act at the end of 2013. The Compounding Quality Act which first removes certain provisions from section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) that were found to be an unconstitutional restraint of commercial free speech by the U.S. Supreme Court in Thompson v. Western States Med. Ctr., 535 U.S. 357 (2002).

Subsequent lower court decisions were split over whether 503A was unconstitutional in its entirety or only in part. The Compounding Quality Act clarifies this issue by eliminating the controversial advertising prohibition.

Section 503A otherwise remains unchanged, and continues to set out the requirements for 
traditional compounding created in the FDCA – the pharmacist must compound the drug for 
individual patients based on a prescription (or a prescription history of an individual or order 
history of a physician). One of the FDA guidance documents addresses traditional compounding 
and is clear that traditional compounding will generally remain under state pharmacy board 
oversight as long as the compounding facility meets the requirements of 503A. A pharmacy that 
compounds in compliance with the 503A requirements is exempt from federal good 
manufacturing practice (cGMP) requirements, adequate directions for use, and new drug 
approval requirements. 

Secondly, the Compounding Quality Act adds a new section 503B to the FDC 
Act, 21 U.S.C. § 353b, to create a new regulatory classification of compounding facilities called 
“outsourcing facilities,” which are to be overseen by FDA instead of state pharmacy boards. 
Unlike traditional compounding pharmacies, outsourcing facilities can compound medications 
without a patient-specific prescription and sell such products to hospitals and other health care 
providers. While an outsourcing facility is exempt from FDA approval requirements and 
adequate directions for use, it is subject to cGMP requirements and will be inspected by the FDA 
according to a risk-based schedule.

Paddy Deighan J.D. Ph.D
http://www.medicalandspaconsulting.com

Friday, May 9, 2014

Lasers Aid in the Delivery of Medication

There is yet another use for laser. Laser has revolutionized medicine and the additional apllications of light based devices seems limitless. Laser-assisted drug delivery can enhance the permeation of topically applied agents, according to a review published in the April issue of Lasers in Surgery and Medicine. This has the potential to be an astounding turn f events. 

Lindsay R. Sklar, M.D., from the Henry Ford Hospital in Detroit, and colleagues conducted a literature review to assess the existing applications of laser-assisted drug delivery.



The researchers found that lasers are a safe and effective means of enhancing the delivery of topically applied agents through the skin. The most commonly used lasers for drug delivery are the carbon dioxide and erbium:yttrium-aluminum-garnet lasers. Laser pretreatment of the skin can increase the permeability and depth of penetration of topically applied drug molecules for both local cutaneous and systemic applications, according to multiple studies.

"Laser-assisted drug delivery is an evolving technology with potentially broad clinical applications," the authors write.One author disclosed financial ties to the laser industry.

Paddy Deighan J.D. Ph.D

Monday, September 23, 2013

Professional Staff in a Spa..Employee or Independent Contractor: An Analysis

The employee/Independent contractor scenario in spas and medical spas is very complex. The determination of whether a professional staff member is an employee or independent contractor is not easy to address. One thing that IS clear; the agreement that may be in effect is not the most significant issue. You can cal a professional staff member whatever you want to call them in an agreement, but this does nt control the ultimate determination.

Many owners and professional staff want to be independent contractors but the reality is in many cases, the relationship is not sustainable and the Internal Revenue Service has been looking at the spa industry more closely (possibly due in large part to tipping structures, but they are looking at the industry). The Service has been looking at many “tip” based businesses such as the taxi industry, restaurants and salons and spas.

The IRS has ruled sometimes that an independent contractor was really an employee because the business supplied TOWELS and LINEN! WOW!



A fundamental approach will be based on two key aspects of the relationship: 1. "control" over the professional staff members hours and days of service, and 2. requirement to utilize certain product lines or practice policies and protocols for certain procedures.

These are not easy issues to address because there are conflicting issues and goals. On one hand, the spa needs staff to be available during operational hours. It would be problematic to allow professional staff to decide the days and hours of service. However, providing schedule is a strong element of “control” over the staff member and this tends to be an employment situation.

The second issue is no less problematic.  A professional staff member may support a certain product line that is not offered by the facility. He or she may have a different protocol for a procedure.  The professional staff member may have his or her own protocols for a procedure – even something as seemingly straight forward as micro-dermasbrasion.  An ancillary concern is when there is a mixture of employees and contractors. The contractors may have more freedom to perform services and procedures and they deem appropriate and this can cause staff problems.

I address many such issues every day and please see my websitehttp://www.medicalandspaconsulting.com

Paddy Deighan J.D. Ph.D

Saturday, September 21, 2013

Awesome Quote from History

I am frequently astounded that quotes from history...quotes that may have been made hundreds of years ago, are still true today (if not truer today). I was watching a history program on late night cable and there was a quote from Thomas Jefferson that rally caught my attention.  Mr. Jefferson stated: “My reading of history convinces me that most bad government results from too much government.” 
How did he know this type of thing? How could they be so acutely aware of the affect of anything on the future. I suppose that some things are fundmanetal and apparently, Mr Jerfferson stated this after reading history. Perhaps we all need to read a little more history.
Sooooo, I decided to read a few more quotes from Mr. Jefferson since has many quotes as they pertain to government and because I have had a fascination about him since graduate school at WIlliam and Mary.  He was a tall man yet his desk at William and Mary is tiny!!!! I always wanted to try and sit in it (it is roped off of course)!!!

Paddy Deighan J.D. Ph.D

Friday, September 20, 2013

The Line Between Medical and Aesthetic Procedures: What Can an Esthetician do?

I am frequently asked to comment on the distinction between what is medical and what is aesthetic (non-medical)....the lines are blurry but in my opinion, they are being violated on a daily basis. The practice of medicine is relatively easy to define....it is the diagnosis OR treatment of a medical condition.  Good, bad or indifferent, acne, rosacea, eczema are medical conditions. Some things may not be as clear...for example, treating "razor bumps" MAY not be medical, but on the other hand, those "razor bumps" are follicultis barbae and then they would be medical. Frustrating...I know.

Additionally, the next level of analysis would be whether any medical device or product is being utilized in the treatment and of so, what federal classification is the device. Virtually all aesthetic lasers AND IPLs are Class II or Class IIb medical devices and they have to be owned and operated by licensed physicians (not RNs). Physicians may, in certain circumstances, delegate "operation" (but not ownership) to other individuals.

Many products are medical...Botox Cosmetic is a prescription drug...100% medical. The dermal fillers (Restylane for example) are all medical PRODUCTS (not a drug). They are still 100% medical but for a different reason.



In laser, you can look at two different types of scenarios...let's use laser hair removal and the treatment of leg veins.  Laser hair removal is NOT a medical procedure. However, if the patient is hirsute because of poly cystic ovary syndrome (PCOS), then it IS medical.  In this situation the treatment may not be medical but the device IS medical. Hence, laser hair removal IS medical.

Treatment of leg veins...this is both a medical treatment and a medical device. Two reasons not to perform this service.

With peels, it gets REALLY complex...one analysis would be to look at FDA guidelines. In 1996 the FDA concluded that "medical" is a product that penetrated the epi-dermal/dermal junction. They concluded that a 30% glycolic treatment achieves this. Prior to 1996, they mandated that a 40% glycolic solution achieved this. But what 30% glycolic? pure 30%, neutralized or buffered 30%?...remain unanswered. Soooo, if you utilize a 40% glycolic solution but you know that it is neutralized or buffered, then you are probably OK.

Jessner's peels and most TCA peels are mid-to high level strength peels and they are medical. Sal acid is non medical unless in high strengths....hydro quinones are non medical if they are under 2%...we could go on for hours...topical anesthetics can be medical or non medical too...depending upon the strength and formulation (this is actually a HUGE issue)

The problem is that regulation comes in the form of....state statutes, state and federal case law, federal mandate (FDA, FTC), state boards of medicine, cosmetology and nursing, Attorney General reports and cases...WHEW. There is no ONE place to look!

Recently, there was a discussion and an esthetician commented to me that she contacted her state board in NH. They said that as long as she was certified, it was OK for her to perform the procedure (I do not recall the specific procedure, but on its face, it was medical ...blade or syringe was utilized if I recall). That may have been true by NH board purposes, but federal law would disagree and Federal law trumps state law.

Paddy Deighan J.D. Ph.D

Thursday, September 5, 2013

Important HIPAA Lawsuit Update

Although HIPAA does not create a private cause of action, a recent Indiana Superior Court jury verdict indicates that HIPAA could still play an important role in private causes of action in state court based on negligence and professional liability as it relates to confidentiality. On July 26, a jury in Marion County, Indiana awarded $1.44 million to a Walgreens customer based on allegations that the customer’s pharmacist accessed, reviewed, and shared the customer’s prescription history with others who then used the information to intimidate and harass the customer. At the heart of the case was a tangled love triangle in which the pharmacist’s husband had previously been romantically involved with the customer, resulting in the birth of a child. When the pharmacist learned of the relationship, she allegedly accessed the customer’s prescription information and shared it with her husband, who then used the information to intimidate the customer when she began demanding child support payments.
The customer filed suit against both the pharmacist and Walgreens in Indiana Superior Court, claiming that both parties had breached their statutory and common law duties of confidentiality and privacy. The complaint also included claims of negligence, invasion of privacy, and publication of private facts against the pharmacist and claims of negligent training, supervision, and retention against Walgreens for continuing to employ the pharmacist even after discovering the incident. The Court granted Walgreens’ Motion for Summary Judgment on the negligent training claim
At trial, Plaintiff argued that even though HIPAA did not create a private cause of action, it still defined the standard of care for a pharmacist’s duty of confidentiality and privacy to Plaintiff’s health information. Thus, according to Plaintiff, because the pharmacist’s actions violated HIPAA, the pharmacist had breached the standard of care and should therefore be held liable for the harm caused to Plaintiff. Additionally, because the pharmacist had acted within the scope of her employment, Plaintiff argued that Walgreens was also liable for the pharmacist’s actions. After a four day trial, the jury agreed on both points, awarding $1.44 million in damages to Plaintiff. Walgreens intends to appeal the verdict.
This is not the first case in which HIPAA has been the centerpiece of a private cause of action, but it does appear to be the first case resulting in a substantial jury verdict against a provider using HIPAA as the basis for the standard of care. Whether and to what extent HIPAA can be used to establish the standard of care in a professional liability, negligence, or other breach of professional duty case will be dependent on state tort law, and the outcome of this case on appeal is unpredictable. Nonetheless, as HIPAA continues to receive attention from trial lawyers seeking to establish the standard of care in negligence and professional liability cases involving the improper disclosure of health information, health care providers must be aware that, depending on the law of the state in which they are licensed, their potential liability for HIPAA violations could extend beyond Civil Monetary Penalties.



Paddy Deighan J.D. Ph.D

Wednesday, September 4, 2013

Genetics Play a Role in Stretch Marks: Treatment Update

23andMe, a leading consumer oriented personal genetics company, has conducted the first genetic study of striae distensae (stretch marks). Researchers at the company identified four genetic markers significantly associated with the development of stretch marks that inform why some individuals are more susceptible to the skin condition.

Estimates of the prevalence of stretch marks range from 50-80 percent.  The exact causes of stretch marks are still widely unknown. Many factors, including excessive skin distension (during pregnancy, growth spurts, rapid weight gain), prolonged exposure to cortisol and genetics are thought to play a role.


Popular treatments, including topical creams and laser treatment often focus on stimulating collagen production to decrease the appearance of stretch marks. The strong association between (the breakdown) of elastin and stretch marks discovered through this research offers an opportunity to improve methods to prevent and treat stretch marks. However these treatments yield little visible results and patient satisfaction is exceedingly low with these modalities.  Cocoa butter?? Why bother!

There are effective treatments on the horizon and we will be discussing them in detail. 

"To date, no genetic variants were known to be associated with isolated stretch marks that affect the general public," said Joyce Tung, Ph.D., author and 23andMe Director of Research. "Through this first of its kind study, we've identified new genetic associations that can provide deeper insights into the root causes of stretch marks, and look forward to continuing research in this space. One intriguing area for further study is the potential effect of genes associated with obesity on the development of stretch marks, both independent of and via changes in Body Mass Index. Replicating this work in a more precisely phenotyped population would also be a logical next step."


23andMe conducted a genome-wide association analysis across 33,930 unrelated 23andMe customers of European descent; within the sample there were a total of 13,930 cases and 20,862 controls. Because loose skin is a symptom of syndromes caused by deletion or loss-of-function mutations in elastin, it is likely that variations in the elastic fiber component of the skin extracellular matrix contribute to the development of stretch marks. The expression of collagens, elastin and fibronectin is also decreased in striae, which could be linked to the reorganization and overall loss of elastic fibers in skin affected by stretch marks.

Paddy Deighan, J.D. Ph.D